Effects of Lidocaine derivatives on cancer pain; the specific blockade of primary sensory neurons expressing transient receptor potential channels.

2015 Fiscal Year Final Research Report

• Project/Area Number: 25860199
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: General pharmacology
• Research Institution: National Cancer Center Japan
• Principal Investigator: Miyano Kanako 国立研究開発法人国立がん研究センター, 研究所, 研究員 (50597888)
• Project Period (FY): 2013-04-01 – 2016-03-31
• Keywords: TRP / 疼痛 / がん / 抗がん剤 / 末梢神経障害

Outline of Final Research Achievements

There are not many cancer patients receiving well-controlled pain management, and therefore the development of more effective analgesics are required now. In recent years, it revealed that transient receptor potential (TRP) channels expressing primary sensory neurons played an important role for cancer pain. Moreover, it was reported that QX-314, which was one of the derivatives of lidocaine, a local anesthetic, suppressed the activation of voltage-gated sodium channel (Nav) in neurons expressing both TRP and Nav. However, the detailed pharmacological and/or analgesic actions of lidocaine derivatives are not well known.
In this study, therefore, we focused on the derivatives of lidocaine for development of novel analgesics, which specifically block TRP-expressing nerves, and evaluated the pharmacologic actions of these lidocaine derivatives on cancer pain.

Free Research Field

薬理学